Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2

Conditions

Myeloproliferative Disorders 4Primary Myelofibrosis 3Thrombocythemia, Essential 1Polycythemia Vera 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine 19Whole-Body Irradiation 18Cyclophosphamide 17fludarabine phosphate 16ruxolitinib 15Mycophenolic Acid 14Specimen Handling 13Tacrolimus 11Azacitidine 11Biopsy 10Peripheral Blood Stem Cell Transplantation 9Melphalan 9Cytarabine 9venetoclax 8Sirolimus 8Busulfan 8Stem Cell Transplantation 6Injections 6Granulocyte Colony-Stimulating Factor 6Daunorubicin 5Cyclosporine 5CPX-351 5luspatercept 4ivosidenib 4itacitinib 4fedratinib 4decitabine and cedazuridine drug combination 4Thiotepa 4Liposomes 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × fedratinib × 1 year × Clear all
NCT05177211 2026-04-17

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Neutrophilic, Chronic

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05127174 2025-12-04

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
12 enrolled
Myeloid

Myeloproliferative Disorders

NCT03952039 2025-08-28

FREEDOM2

Celgene

Phase 3 Completed
202 enrolled 23 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡